Skip to main content
. 2022 Aug 10;12(8):1099. doi: 10.3390/biom12081099

Table 1.

Clinical and biochemical data of the subjects (serum subpopulation).

Non-AD AD p Value
Gender (males/females) 16 (7/9) 10 (5/5) NS 1
Age (years) 67.0 ± 12.3 68.5 ± 16.1 NS 2
Disease Duration (years) 2.96 ± 1.27 3.88 ± 2.50 NS 2
MMSE 23.3 ± 8.50 15.5 ± 8.80 0.034 2
Serum τP-181 (pg/mL) 2.16 ± 1.77 3.01 ± 0.83 NS 2
CSF Aβ (z-score) −0.49 ± 1.52 −1.63 ± 1.21 0.056 2
CSF τP-181 (z-score) 0.11 ± 0.92 3.51 ± 2.48 <0.0001 2
CSF τΤ (z-score) 0.25 ± 1.12 2.53 ± 2.47 0.004 2

Results are presented as mean ± standard deviation. AD: Alzheimer’s Disease, MMSE: Mini Mental State Examination, CSF: Cerebrospinal fluid, Aβ: either Aβ42/Aβ40 or Aβ42 alone (when Aβ40 was not available), τP-181: tau protein phosphorylated at a threonine residue at position 181, τΤ: total tau protein, NS: non-significant. 1 χ2-test, 2 t-test.

HHS Vulnerability Disclosure